Ongoing Phase III Study Could Provide Xinlay Back-Up Option, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA reject the current application, which uses a meta-analysis of subgroups from two failed trials